Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Neurologic Symptoms Linked With Death in Pediatric Leukemia Neurologic Symptoms Linked With Death in Pediatric Leukemia
Neurologic manifestations such as headache, neuropathy, seizures, and cell infiltration are common in pediatric patients with acute leukemia and are associated with a higher mortality rate, data show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 2, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves Olutasidenib (Rezlidhia) for Certain Patients With AML FDA Approves Olutasidenib (Rezlidhia) for Certain Patients With AML
The drug has been approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 2, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Rezlidhia (olutasidenib) for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
December 1, 2022 -- On December 1, 2022, the Food and Drug Administration (FDA) approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 1, 2022 Category: Drugs & Pharmacology Source Type: news

Novel Co-Admin of CAR T Cells Achieves 99% Remission in Leukemia Novel Co-Admin of CAR T Cells Achieves 99% Remission in Leukemia
In the largest study to date of CAR T-cell therapy for relapsed and refractory childhood B-cell acute lymphoblastic leukemia, a novel approach led to undetectable disease in nearly all patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 8, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

“ Why Aren ’ t We All Bacteria? ” Siddhartha Mukherjee Explores the Power of Cells
It’s hard to miss what appears to be dry cleaning hanging on the wall of Siddhartha Mukherjee’s apartment in New York City’s Chelsea neighborhood. The apartment is a sunny, stylish, open space, filled with modern furniture, decorated with sculpture and paintings—and then, in perhaps the most conspicuous spot on the living room, is a brown felt suit with very long pants, draped over a plain wooden hanger. It looks entirely out of place—but it’s not. The suit is the handiwork of German artist Joseph Bueys, who created the improbable bit of fabric art as a tribute to the nomadic Tatars who,...
Source: TIME: Science - October 31, 2022 Category: Science Authors: Jeffrey Kluger Tags: Uncategorized Magazine Science Source Type: news

‘ Why Aren ’ t We All Bacteria? ’ Siddhartha Mukherjee Explores the Power of Cells
It’s hard to miss what appears to be dry cleaning hanging on the wall of Siddhartha Mukherjee’s apartment in New York City’s Chelsea neighborhood. The apartment is a sunny, stylish, open space, filled with modern furniture, decorated with sculpture and paintings—and then, in perhaps the most conspicuous spot on the living room, is a brown felt suit with very long pants, draped over a plain wooden hanger. It looks entirely out of place—but it’s not. The suit is the handiwork of German artist Joseph Bueys, who created the improbable bit of fabric art as a tribute to the nomadic Tatars who,...
Source: TIME: Science - October 31, 2022 Category: Science Authors: Jeffrey Kluger Tags: Uncategorized Magazine Science Source Type: news

Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Iomab-B met the primary endpoint of durable complete remission of 6-months following initial complete remission after HCT with a p-value of ... Biopharmaceuticals, Oncology Actinium Pharmaceuticals, Iomab-B, targeted radiotherapies, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 31, 2022 Category: Pharmaceuticals Source Type: news

St. Jude Children ’s Research Hospital has a new clinical trial for relapsed leukemia
A specific type of drug-resistant, relapsed pediatric cancer is the focus of a new clinical trial at St. Jude Children's Research Hospital. The phase I/II clinical trial called RAVEN aims to research a new treatment option for children with relapsed acute lymphoblastic leukemia (ALL) — a severe cancer of blood and bone marrow that attacks white blood cells. According to Dr. Seth Karol, the trial's principal investigator and St. Jude associate faculty member, RAVEN uses a combination of traditional… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 27, 2022 Category: Biotechnology Authors: Aishwarya Airy Source Type: news

Your Gas Stove May Be Leaking Benzene Into Your Kitchen —Even When It ’ s Off
The U.S. goes through a lot of natural gas, consuming more than 30 trillion cubic feet of it last year, according to the U.S. Energy Information Administration—about 15% of which is burned by home appliances. On top of climate concerns—natural gas may be less carbon polluting than coal, but the methane released during production is a powerful greenhouse gas in its own right—there is a growing awareness of the risk this gas poses to our health. According to a new study published today in the journal Environmental Science and Technology, not only the atmosphere, but your kitchen may be a victim of contamina...
Source: TIME: Health - October 20, 2022 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Group salesup 2%[1] at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye diseases)US approval...
Source: Roche Investor Update - October 18, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Basel, 18 October 2022Group salesup 2%1 at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye ...
Source: Roche Media News - October 18, 2022 Category: Pharmaceuticals Source Type: news

Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment
This final guidance is intended to assist sponsors in the clinical development of drugs and biological products for the treatment of AML. This guidance addresses FDA ’s current thinking regarding the overall development program and clinical trial designs for AML drugs. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 17, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Cesarean Section Tied to Higher Risk for Later Leukemia in Offspring
Findings strongest for elective cesarean section and acute lymphoblastic leukemia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 15, 2022 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Internal Medicine, Oncology, Pediatrics, Surgery, Journal, Source Type: news